CASI Pharmaceuticals, Inc. (CASI): Price and Financial Metrics


CASI Pharmaceuticals, Inc. (CASI): $2.04

0.05 (+2.51%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CASI to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CASI POWR Grades

  • CASI scores best on the Sentiment dimension, with a Sentiment rank ahead of 98.41% of US stocks.
  • The strongest trend for CASI is in Sentiment, which has been heading up over the past 86 days.
  • CASI's current lowest rank is in the Momentum metric (where it is better than 3.73% of US stocks).

CASI Stock Summary

  • CASI PHARMACEUTICALS INC's market capitalization of $27,076,199 is ahead of merely 8.6% of US-listed equities.
  • With a year-over-year growth in debt of 176.75%, CASI PHARMACEUTICALS INC's debt growth rate surpasses 92.12% of about US stocks.
  • The volatility of CASI PHARMACEUTICALS INC's share price is greater than that of 92.56% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to CASI PHARMACEUTICALS INC are CDNA, SMRT, VMEO, WRAP, and AMST.
  • CASI's SEC filings can be seen here. And to visit CASI PHARMACEUTICALS INC's official web site, go to www.casipharmaceuticals.com.

CASI Valuation Summary

  • In comparison to the median Healthcare stock, CASI's price/sales ratio is 65.85% lower, now standing at 0.7.
  • Over the past 243 months, CASI's EV/EBIT ratio has gone up 0.4.

Below are key valuation metrics over time for CASI.

Stock Date P/S P/B P/E EV/EBIT
CASI 2023-01-20 0.7 0.4 -1 0.0
CASI 2023-01-19 0.7 0.4 -1 0.0
CASI 2023-01-18 0.7 0.4 -1 0.0
CASI 2023-01-17 0.8 0.5 -1 -0.1
CASI 2023-01-13 0.7 0.4 -1 0.0
CASI 2023-01-12 0.7 0.4 -1 -0.1

CASI Growth Metrics

    The 2 year net income to common stockholders growth rate now stands at 32.25%.
  • Its 3 year price growth rate is now at -90.19%.
  • The 5 year net cashflow from operations growth rate now stands at -270.66%.
CASI's revenue has moved up $37,006,000 over the prior 49 months.

The table below shows CASI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 37.006 -27.886 -27.078
2022-06-30 34.905 -25.222 -32.101
2022-03-31 33.494 -23.079 -31.367
2021-12-31 30.168 -26.842 -36.654
2021-09-30 25.832 -27.233 -45.252
2021-06-30 21.962 -30.203 -51.981

CASI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CASI has a Quality Grade of F, ranking ahead of 3.6% of graded US stocks.
  • CASI's asset turnover comes in at 0.158 -- ranking 218th of 682 Pharmaceutical Products stocks.
  • DRNA, RARE, and ALNY are the stocks whose asset turnover ratios are most correlated with CASI.

The table below shows CASI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.158 0.585 -0.969
2021-03-31 0.139 0.505 -1.192
2020-12-31 0.134 0.372 -1.351
2020-09-30 0.109 0.242 -1.615
2020-06-30 0.101 0.053 -1.638
2020-03-31 0.070 0.052 -2.024

CASI Price Target

For more insight on analysts targets of CASI, see our CASI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.45 Average Broker Recommendation 1.25 (Strong Buy)

CASI Stock Price Chart Interactive Chart >

Price chart for CASI

CASI Price/Volume Stats

Current price $2.04 52-week high $10.30
Prev. close $1.99 52-week low $1.45
Day low $2.02 Volume 12,200
Day high $2.05 Avg. volume 35,133
50-day MA $1.87 Dividend yield N/A
200-day MA $2.94 Market Cap 27.76M

CASI Pharmaceuticals, Inc. (CASI) Company Bio


CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, acquires, develops, and commercializes therapeutics addressing cancer and other unmet medical needs in China. The company was founded in 1991 and is based in Rockville, Maryland.


CASI Latest News Stream


Event/Time News Detail
Loading, please wait...

CASI Latest Social Stream


Loading social stream, please wait...

View Full CASI Social Stream

Latest CASI News From Around the Web

Below are the latest news stories about CASI PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CASI as an investment opportunity.

Casi Pharmaceuticals to run clinical trial for multiple myeloma drug in China

MARKET PULSE Shares of Casi Pharmaceuticals Inc. (CASI) were up 10% in premarket trading on Friday after the company said China will allow a Phase 1 clinical trial evaluating a multiple myeloma drug developed by the privately held Cleave Therapeutics.

Yahoo | January 6, 2023

CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announces that the China National Medical Products Administration (NMPA) has approved the Company's Clinical Trial Application (CTA) for CB-5339, a first-in-class VCP/p97 inhibitor from Cleave Therapeutics. CASI is planning a Phase 1 development program in China of CB-5339 as a single agent to evaluate the PK/safety profile, se

Yahoo | January 6, 2023

CASI PHARMACEUTICALS' PARTNER JUVENTAS ANNOUNCES NEW DRUG APPLICATION FOR CNCT19 ACCEPTED BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces that China National Medical Products Administration (NMPA) has accepted the new drug application (NDA) from Juventas Cell Therapy, Ltd., (Juventas) for CNCT19 (Inaticabtagene Autoleucel), an investigational CD-19 directed CAR-T therapy, for the treatment of adult patients with relapsed/refractory B-Cell Acute Ly

Yahoo | December 15, 2022

CASI Pharmaceuticals Third Quarter 2022 Earnings: Beats Expectations

CASI Pharmaceuticals ( NASDAQ:CASI ) Third Quarter 2022 Results Key Financial Results Revenue: US$10.2m (up 26% from 3Q...

Yahoo | November 17, 2022

CASI Pharmaceuticals, Inc. (CASI) Reports Q3 Loss, Lags Revenue Estimates

CASI Pharmaceuticals, Inc. (CASI) delivered earnings and revenue surprises of 25.49% and 1.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 14, 2022

Read More 'CASI' Stories Here

CASI Price Returns

1-mo 28.30%
3-mo 4.62%
6-mo -17.41%
1-year -65.42%
3-year -93.11%
5-year -94.73%
YTD 13.97%
2022 -77.63%
2021 -72.88%
2020 -4.53%
2019 -23.13%
2018 23.69%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6841 seconds.